Signet Healthcare Partners has made a growth investment in Juno Pharmaceuticals Corp, a Toronto-based specialty generics pharmaceuticals company. No financial terms were disclosed. Juno specializes in bringing complex and high-value generic and biosimilar products to the Canadian market.
PRESS RELEASE
TORONTO–Juno Pharmaceuticals Corp (“Juno”), a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth.
James Gale, Managing Director of Signet said, “We are very pleased with the opportunity to partner with the Juno management team. They have decades of pharmaceutical industry experience and have built a growing business. They have done so through astute product selection and a disciplined approach to building their pipeline. We look forward to contributing to this effort.”
Ian Jacobson, Chief Executive Officer of Juno noted, “I am very happy to welcome Signet as a key investor in the future of Juno. We believe Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics. We look forward to working with the Signet team building Juno into one of the leading generic pharmaceutical companies in Canada.”
Aird & Berlis LLP acted as legal counsel for Juno Pharmaceuticals Corp and Sheppard, Mullin, Richter & Hampton LLP acted as legal counsel for Signet Healthcare Partners.
About Juno Pharmaceuticals Corp
Juno Pharmaceuticals Corp specializes in bringing complex and high value generic and biosimilar products to the Canadian market. The Juno management team possesses decades of pharmaceutical industry experience along with an extensive track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. An early member of the global Juno Pharmaceuticals group, Juno’s global operations span four continents and consist of over 10 diverse pharmaceutical and medical device businesses spread across Canada, the United Kingdom, the European Union, Australia and South Africa.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.